MSD's pulmonary arterial hypertension (PAH) drug Winrevair has been accelerating at a breakneck pace since its launch earlier this year – and data from a new phase 3 study could give it a turbo boost.

NEW YORK--(BUSINESS WIRE)--Engine Capital LP (together with its affiliates, “Engine” or “we”), which owns approximately 3% of the outstanding shares of Acadia Healthcare Company, Inc. (NASDAQ: ACHC) ( ...

We independently review everything we recommend. When you buy through our links, we may earn a commission. Learn more› By Kit Dillon and Wirecutter Staff We’ve updated our sunscreen picks. Also, our ...